CellaVision AB (publ), which develops and sells digital morphology products for the routine analysis of blood and other body fluids, today announced that David Autry has been appointed President of CellaVision North America, with start on May 4, 2009.
Mr. Autry will be responsible for the CellaVision operations in North America including the U.S. and Canadian subsidiaries based in Jupiter, Florida and Toronto, Ontario, respectively. Mr. Autry will report directly to Yvonne Mårtensson, President and CEO of CellaVision AB.
"I am very pleased that Dave Autry has chosen to join the CellaVision North America team", says Yvonne Mårtensson. "Dave brings to CellaVision his proven ability to lead top performing teams and his successful track record with over 20 years of line management experience in the medical technology industry. The new position is a result of the strategic decision to invest in our own sales organizations in the North American markets. We expect significant growth over the next years from the US and Canadian markets and are looking forward to Dave's leadership in achieving this growth."
Prior to joining CellaVision Mr. Autry was VP Sales and Marketing of Ikonisys Inc., a start-up within imaging and analysis instrumentation for FISH-processed slides. Before Ikonisys, Mr. Autry successfully built up Australia's Vision BioSystems, in the Americas. He also was VP North America of Cytologix and Sales Director of Dako Corp. in Carpinteria, CA. Mr. Autry also served in a number of sales and marketing management positions in several diagnostic and medical device companies.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.
The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com
CellaVision's share is listed on First North Premier at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.